Why is Glenmark Pharma falling/rising?

As of 07-Aug, Glenmark Pharmaceuticals Ltd. has seen its stock price rise to 2,070.50, reflecting an increase of 46.1 or 2.28%. The stock has outperformed its sector today by 1.63% and has experienced a trend reversal after two consecutive days of decline. Despite a recent drop in delivery volume, which fell by 70.59% against the 5-day average, the stock remains liquid enough for trading. Over the past month, Glenmark has delivered a strong return of 11.18%, significantly outperforming the Sensex, which declined by 3.38%. The company has shown consistent performance, with a remarkable 41.76% return over the past year, supported by a substantial profit growth of 241.1%.
In the broader market context, Glenmark's short-term performance contrasts sharply with the benchmark, as it has risen while the Sensex has seen a slight decline of 0.69% over the past week. The company's strong fundamentals, including a low Debt to EBITDA ratio of 1.00 and positive results for the last four consecutive quarters, contribute to its favorable valuation compared to peers. Additionally, high institutional holdings at 38.3% indicate confidence from knowledgeable investors, further supporting the stock's upward movement. Overall, Glenmark's consistent returns and positive financial metrics have positioned it well in the market, contributing to its recent price increase.